Mineralys Late Results for Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension

 

• Mineralys Therapeutics (MLYS, Financial) unveils significant results from its Phase 3 Launch-HTN trial for lorundrostat in treating uncontrolled or resistant hypertension.
• Lorundrostat 50mg reduced systolic blood pressure by 16.9 mmHg at Week 6 and 19.0 mmHg at Week 12.
• Only 0.1% of participants experienced treatment-related serious adverse events, indicating a favorable safety profile.

https://www.gurufocus.com/news/2887320/mineralys-therapeutics-announces-latebreaking-presentation-of-data-from-the-launchhtn-pivotal-trial-of-lorundrostat-in-uncontrolled-or-resistant-hypertension-at-34th-european-meeting-on-hypertension